Janssen Search
Search results
Avrum Spira, M.D., M.Sc.
AVRUM SPIRA, M.D., M.Sc. GLOBAL HEAD LUNG CANCER INITIATIVE AT JOHNSON & JOHNSON AND WORLD WITHOUT DISEASE ACCELERATOR Avrum “Avi” Spira, M.D., M.Sc. is the Global Head of Johnson & Johnson’s cross-sector Lung Cancer Initiative (LCI). The vision ...
Why it’s Important to Celebrate International Women’s Day
Why it’s Important to Celebrate International Women’s Day Recently, we celebrated International Women's Day (IWD), a global awareness day paying special tribute to the social, economic, cultural and political achievements of women. IWD is ...
Machine Learning
By leveraging state-of-the-art machine learning techniques to recognize complex patterns in vast amounts of data, we can more effectively and efficiently develop innovative therapies for patients. Machine Learning Machine learning has been defined as the ...
Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis
Mar 11, 2024 United States Submission is supported by data from the Phase 3 QUASAR program, which showed a significantly greater percentage of patients with moderately to severely active ulcerative colitis who received TREMFYA ® achieved clinical ...
U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1
Mar 19, 2024 United States This approval offers a new HIV-1 treatment option for children in the U.S. at least 2 years of age, weighing 14 kg – 25 kg and living with HIV Titusville, NJ (March 19, 2024) – Johnson & Johnson today announced that the U.S. ...
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX®
Jun 04, 2024 If approved, PREZCOBIX® would offer a new HIV-1 treatment option for pediatric patients aged 6 and older weighing at least 25 kg Titusville, N.J. (June 4, 2024) – Johnson & Johnson today announced the submission of a supplemental New Drug ...
Johnson & Johnson’s nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)
Feb 09, 2024 United States Breakthrough Therapy Designation for nipocalimab based on results from the Phase 2 UNITY clinical trial for HDFN Phase 3 clinical trial enrollment underway, representing the only therapy reported to be under clinical development ...
Commitment to Immunodermatology Newsroom
Welcome to the Johnson & Johnson Immunodermatology Newsroom! Below, please find the latest data, content, meeting news and leadership messages about our progress and commitment to developing transformational approaches and innovative medicines for ...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn’s disease
Jun 21, 2024 Submission is supported by 48-week results from the Phase 3 GALAXI and GRAVITI programs TREMFYA® is the only IL-23 inhibitor to demonstrate strong endoscopic outcomes with subcutaneous (SC) induction, consistent with intravenous (IV) ...
Story – Mental Health Initiatives
Developing Solutions and Creating Access for People With Mental Illness From research to real-world solutions, Janssen has a legacy of developing treatments for mental illnesses. For more than 50 years, our unwavering commitment to mental health has led ...